This webinar discusses the evolving options for BTK inhibitors in Chronic Lymphocytic Leukemia (CLL) based on a transcript of a medical discussion. The conversation revolves around two patient cases and provides insights into the treatment decision-making process. Here are the key points:

  1. Introduction to CLL Treatment: The discussion highlights that CLL treatment is rapidly evolving, making it essential for healthcare providers to stay updated on the latest therapies and research.
  2. Patient Case 1: A 74-year-old woman with CLL who presents with fatigue and an enlarged spleen. The transcript covers various treatment options, including covalent BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib, and discusses considerations based on comorbidities, age, and patient preferences.
  3. Patient Case 2: A 54-year-old man with relapsed and progressive CLL. The discussion revolves around whether to initiate therapy immediately, the choice of BTK inhibitors, and the potential use of second-generation BTK inhibitors.
  4. Duration of Treatment: The webinar emphasizes the importance of discussing the course of treatment with patients, including the possibility of time-limited therapy based on evolving research.
  5. Ongoing Monitoring and Adaptation: The conversation underscores the need for continuous patient monitoring, close attention to side effects, and flexibility in treatment plans based on individual patient responses.
  6. Future Developments: The healthcare providers acknowledge that the field of CLL treatment is continuously evolving, with new therapies and insights emerging. Staying informed about the latest research is crucial for providing the best care.

Overall, the webinar provides valuable insights into the decision-making process for CLL treatment, emphasizing the importance of patient-centered care and adaptability in the rapidly changing landscape of CLL therapy.


Supported by

In partnership with